Effectiveness and Safety of a Mixture of Nobiletin and Tangeretin in Nocturia Patients: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study

被引:5
|
作者
Ito, Haruki [1 ]
Negoro, Hiromitsu [2 ]
Kono, Jin [3 ]
Hayata, Naoki [1 ]
Miura, Takayoshi [1 ]
Manabe, Yumi [1 ]
Miyazaki, Yu [1 ]
Mishina, Mutsuki [1 ]
Woo, Je Tae [4 ]
Sakane, Naoki [5 ]
Okuno, Hiroshi [1 ]
机构
[1] Natl Hosp Org, Kyoto Med Ctr, Dept Urol, Kyoto 6128555, Japan
[2] Univ Tsukuba, Inst Med, Dept Urol, Tsukuba 3058575, Japan
[3] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto 6068507, Japan
[4] Chubu Univ, Coll Biosci & Biotechnol, Dept Biol Chem, Kasugai 4878501, Japan
[5] Natl Hosp Org, Clin Res Inst, Kyoto Med Ctr, Div Prevent Med, Kyoto 6128555, Japan
关键词
clinical trial; flavonoid; voiding diary; URINARY-TRACT SYMPTOMS; NETWORK; MEN;
D O I
10.3390/jcm12082757
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nobiletin and tangeretin (NoT) are flavonoids derived from the peel of Citrus depressa, and they have been found to modulate circadian rhythms. Because nocturia can be considered a circadian rhythm disorder, we investigated the efficacy of NoT for treating nocturia. A randomized, placebo-controlled, double-blind, crossover study was conducted. The trial was registered with the Japan Registry of Clinical Trials (jRCTs051180071). Nocturia patients aged >= 50 years who presented nocturia more than 2 times on a frequency-volume chart were recruited. Participants received NoT or a placebo (50 mg once daily for 6 weeks), followed by a washout period of >= 2 weeks. The placebo and NoT conditions were then switched. Changes in nocturnal bladder capacity (NBC) were the primary endpoint, and changes in nighttime frequency and nocturnal polyuria index (NPi) were secondary endpoints. Forty patients (13 women) with an average age of 73.5 years were recruited for the study. Thirty-six completed the study, while four withdrew. No adverse events directly related to NoT were observed. NoT had little effect on NBC compared with the placebo. In contrast, NoT significantly changed nighttime frequency by -0.5 voids compared with the placebo (p = 0.040). The change in NPi from baseline to the end of NoT was significant (-2.8%, p = 0.048). In conclusion, NoT showed little change in NBC but resulted in decreased nighttime frequency with a tendency toward reduced NPi.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Randomized double-blind placebo-controlled crossover study of caffeine in patients with intermittent claudication
    Momsen, A. H.
    Jensen, M. B.
    Norager, C. B.
    Madsen, M. R.
    Vestersgaard-Andersen, T.
    Lindholt, J. S.
    BRITISH JOURNAL OF SURGERY, 2010, 97 (10) : 1503 - 1510
  • [2] Desmopressin in the treatment of nocturia:: A double-blind, placebo-controlled study
    van Kerrebroevk, Philip
    Rezapour, Masoumeh
    Cortesse, Ariane
    Thueroff, Joachim
    Riis, Anders
    Norgaard, Jens Peter
    EUROPEAN UROLOGY, 2007, 52 (01) : 221 - 229
  • [3] A randomized, double-blind, placebo-controlled crossover study on oral ATP administration
    Coolen, Erik
    Arts, Ilja
    Bours, Martijn
    Huyghebaert, Nathalie
    Cohen, Stuart Martien
    Bast, Aalt
    Dagnelie, Pieter
    PURINERGIC SIGNALLING, 2008, 4 : S196 - S197
  • [4] Octreotide in hepatorenal syndrome: A randomized, double-blind, placebo-controlled, crossover study
    Pomier-Layrargues, G
    Paquin, SC
    Hassoun, Z
    Lafortune, M
    Tran, A
    HEPATOLOGY, 2003, 38 (01) : 238 - 243
  • [5] Randomized, double-blind, placebo-controlled crossover study of donepezil in Down syndrome
    Kishnani, PS
    Spiridigliozzi, GA
    Heller, JH
    Sullivan, JA
    Crissman, BG
    Hauser, E
    Grambow, SC
    Doraiswamy, PM
    Krishnan, RR
    NEUROLOGY, 2005, 64 (06) : A106 - A106
  • [6] Estradiol in premenstrual asthma: A double-blind, randomized, placebo-controlled, crossover study
    Ensom, MHH
    Chong, G
    Zhou, DY
    Beaudin, B
    Shalansky, S
    Bai, TR
    PHARMACOTHERAPY, 2003, 23 (05): : 561 - 571
  • [7] Effectiveness of intranasal zolmitriptan in acute cluster headache - A randomized, placebo-controlled, double-blind crossover study
    Cittadini, Elizabeth
    May, Arne
    Straube, Andreas
    Evers, Stefan
    Bussone, Gennaro
    Goadsby, Peter J.
    ARCHIVES OF NEUROLOGY, 2006, 63 (11) : 1537 - 1542
  • [8] A Randomized, Double-Blind, Placebo-Controlled Study of Erenumab Safety in Patients with Stable Angina
    Depre, C.
    Antalik, L.
    Starling, A. J.
    Koren, M.
    Eisele, O.
    Mikol, D.
    HEADACHE, 2018, 58 : 177 - 177
  • [9] Double-Blind, Placebo-Controlled, Crossover Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia
    Krystal, Andrew D.
    Preud'homme, Xavier A.
    SLEEP, 2017, 40 (01)
  • [10] A parallel, randomized, double-blind, placebo-controlled study to investigate the effect of SagaPro on nocturia in men
    Sigurdsson, Steinthor
    Geirsson, Gudmundur
    Gudmundsdottir, Hrefna
    Egilsdottir, Perla B.
    Gudbjarnason, Sigmundur
    SCANDINAVIAN JOURNAL OF UROLOGY, 2013, 47 (01) : 26 - 32